Leukemia lymphoma
Adult t cell leukemia/ lymphoma: from epidemiology to treatment
... cell leukemia / lymphoma virus type 1), an exogenous retrovirus discovered in humans, isolated in the United States, in ...T lymphoma with a leukemic phase (Gessain, ...
6
Case Report Bone marrow infiltration of CD20-negative follicular lymphoma after rituximab therapy: a histological mimicker of hematogones and B-cell acute lymphoblastic leukemia/lymphoma
... In this paper, we report a case of bone marrow infiltration of CD20-negative FL after rituximab administration, which histologically mimicked B-ALL/LBL or hematogones. There are some case reports on CD20 downregulation ...
5
The role of HGF/c-MET signaling pathway in lymphoma
... In addition, the expression of c-MET was found in PBMCs from adult T cell leukemia/lymphoma (ATLL) patients and HTLV-1-infected T cell lines. HGF secreted in paracrine rather than in autocrine mechanism ...
8
Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies
... Abstract: In the last decade, the advent of biological targeted therapies has revolutionized the management of several types of cancer, especially in the realm of hematologic malignancies. One of these pathways, and the ...
10
Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma
... Non-Hodgkin lymphoma; HSP70: Heat shock protein70; BL: Burkitt leukemia/lymphoma; RTK: Receptor tyrosine kinase; PTEN: Phosphatase and tensin homolog deleted on chromosome ten; TSC2: Tuberous ...
7
Combination of BCL11A siRNA with vincristine increases the apoptosis of SUDHL6 cells
... lymphocytic leukemia/lymphoma 11 (BCL11) gene family members, including the BCL11A and BCL11B, have been identified as transcriptional repressors, which are essential for lymphoid development ...cell ...
6
Histiocytic sarcoma combined with acute monocytic leukemia: a case report
... Although HS is a rare disease, many reports in recent years have described HS arising subsequent to or con- current with other neoplasms [3–13], most of which are lymphocytic leukemia/lymphoma. As HS ...
6
<p>Immunochemotherapy for Richter syndrome: current insights</p>
... aggressive lymphoma resem- bling the histology of “reticular cell ...B-cell lymphoma (DLBCL) and less often to Hodgkin’s lymphoma (HL); however, the development of plasmablastic lymphoma (PBL) ...
14
xCELLigence system for real-time label-free monitoring of growth and viability of cell lines from hematological malignancies
... Abstract: The xCELLigence system is a new technological approach that allows the real-time cell analysis of adherent tumor cells. To date, xCELLigence has not been able to monitor the growth or cytotoxicity of ...
10
Targeting CD19 in B-cell lymphoma: emerging role of SAR3419
... lymphoblastic leukemia/lymphoma with or without recurrent genetic abnor- ...(mantle lymphoma), germinal center neoplasm (follicular lymphoma, Burkitt lymphoma, some DLBCL) and ...
9
BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects
... Abstract: The bromodomain and extra-terminal (BET) family of proteins are important epigenetic regulators involved in promoting gene expression of critical oncogenes. BET inhibitors have been demonstrated to repress ...
11
Mutations of c-Cbl in myeloid malignancies
... myelogenous leukemia (AML) characterized by accumulation of immature myeloid cells in the bone marrow, myelodypastic syndromes (MDS) associated with ineffective hematopoiesis and chronic myeloproliferative ...
8
Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions
... CD3 is a pan T cell marker comprised of four distinct polypeptide chains, epsilon, gamma, delta, and zeta, which form pairs of dimers, transmitting T cell activa- tion signals. As CD3 is exclusively expressed on T cells, ...
21
Second primary cancers in non-Hodgkin lymphoma: Bidirectional analyses suggesting role for immune dysfunction.
... unlikely that prior therapy is solely responsible for SPC risk. To investigate risk of SPC after diagnosis of non-Hodgkin lymphoma (NHL) and 10 of its subtypes we conducted a novel bi-directional analysis, SPCs ...
16
A study on lymphoma
... The diagnosis of Hodgkin lymphoma is still made on routine sections, and immunophenotyping studies are an adjunct to the diagnosis. In a morphologically typical case, immunophenotyping studies are not absolutely ...
93
Second-generation inhibitors of Bruton tyrosine kinase
... [70]. The efficacy and safety data on 90 evaluable patients (CLL n = 28, MCL n = 16, DLBCL n = 35, FL n = 5, WM n = 3, MZL n = 2, and SLL n = 1) were reported [68–70, 72]. The dose-escalating 3 + 3 cohorts ranged from 20 ...
7
Clinical Outcomes of 67 Patients Treated with Chemoradiotherapy for Primary Thyroid Non Hodgkin’s Lymphoma in Osaka Medical College
... malignant lymphoma basically depends on pathological evaluation of tissue biopsies, and the new WHO classification of malignant lymphoma has been used since 2008 (Table ...American Lymphoma (REAL) ...
6
Prognostic Impact of the MDM2 Allele in Leukemia and Lymphoma
... The tumor suppressor TP53 is mutated in more than 50% of all human solid tumors and in approximately 30% of patients with leukemia. Notably, p53 has been shown to play a critical role in hematopoiesis. ...
7
Case Report Splenic diffuse red pulp small B-cell lymphoma in an Asian female patient with review of literature
... 4]. Lymphoma cells usually have a CD19+, CD20+, CD22+, CD23-, bcl6-, Annexin1-, CD5-, CD103-, CD123-, CD23-, and CD10- phenotype and frequently express DBA 44, IgG, FMC7 and ...
6
Second lung malignancy and Richter syndrome in chronic lymphocytic leukemia: case report and literature review
... Case presentation: We report a case of a 56-year-old male patient, with history of tobacco smoking, who presented with recurrent hemoptysis, fatigue and weight loss. Physical examination was normal except a slightly ...
5